Skip to content
Screener

PTC Therapeutics PTCT Total Cost of Revenue

Discontinued — last reported Q4 '19

Total Cost of Revenue at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$202.8M+35.1%
ALN
Alnylam PharmaceuticalsALNY
$298.26M+110%
Biogen logo
BiogenBIIB
$776.9M+28.4%
uniQure logo
uniQureQURE
$350K-46.6%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×
P/S+4.7×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: PTC Therapeutics’s 10-K, filed March 2, 2020. Open the filing →

Filed
Mar 2, 2020, 4:40 PM EST
Fiscal year
FY2019
Accession
0001070081-20-000064

FAQ

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.